Cover Image
市場調查報告書

腦膜炎菌血症 - 開發中產品分析

Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 245996
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
腦膜炎菌血症 - 開發中產品分析 Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014
出版日期: 2014年03月31日 內容資訊: 英文 58 Pages
簡介

腦膜炎菌血症是由於腦膜炎所引起的細菌性感染疾病,症狀有發熱、頭痛、麻疹、噁心等。治療有給予抗菌藥及升壓劑,呼吸補助等。

本報告提供腦膜炎菌血症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

腦膜炎菌血症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/實驗室別

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • GlaxoSmithKline plc
  • Biological E. Limited
  • Novartis AG
  • Panacea Biotec Limited
  • Wellstat Vaccines, LLC
  • Beijing Minhai Biotechnology Co., Ltd
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Sanofi Pasteur SA

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Meninge ACYW Conjugate
  • Nimenrix
  • Meningococcal ACW135 Vaccine (Plain)
  • Meningococcal ACYW135 Vaccine (Plain)
  • Meningococcal ACYW135X Vaccine (Plain)
  • MenABCWY Conjugate Vaccine
  • Meningitis Vaccine
  • Meningococcus CY Polysaccharide Conjugate Vaccine
  • Meningococcal B Vaccine
  • ABC Meningococcal Vaccine
  • Meningococcus B Vaccine
  • Meningococcal Vaccine
  • Meningococcal Conjugate Vaccine

開發中產品的最新趨勢

暫停中的計劃

產品開發的里程碑

  • 熱門資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4743IDB

Global Markets Direct's, 'Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014', provides an overview of the Meningococcemia (Meningococcal Infections)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Meningococcemia (Meningococcal Infections)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Meningococcemia (Meningococcal Infections) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Meningococcemia (Meningococcal Infections) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Meningococcemia (Meningococcal Infections) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Meningococcemia (Meningococcal Infections)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Meningococcemia (Meningococcal Infections) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Meningococcemia (Meningococcal Infections) Overview
  • Therapeutics Development
    • Pipeline Products for Meningococcemia (Meningococcal Infections) - Overview
    • Pipeline Products for Meningococcemia (Meningococcal Infections) - Comparative Analysis
  • Meningococcemia (Meningococcal Infections) - Therapeutics under Development by Companies
  • Meningococcemia (Meningococcal Infections) - Therapeutics under Investigation by Universities/Institutes
  • Meningococcemia (Meningococcal Infections) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Meningococcemia (Meningococcal Infections) - Products under Development by Companies
  • Meningococcemia (Meningococcal Infections) - Products under Investigation by Universities/Institutes
  • Meningococcemia (Meningococcal Infections) - Companies Involved in Therapeutics Development
    • GlaxoSmithKline plc
    • Biological E. Limited
    • Novartis AG
    • Panacea Biotec Limited
    • Wellstat Vaccines, LLC
    • Beijing Minhai Biotechnology Co., Ltd
    • Chongqing Zhifei Biological Products Co., Ltd.
    • Sanofi Pasteur SA
  • Meningococcemia (Meningococcal Infections) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Meninge ACYW Conjugate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nimenrix - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal ACW135 Vaccine (Plain) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal ACYW135 Vaccine (Plain) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal ACYW135X Vaccine (Plain) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MenABCWY Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningitis Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcus CY Polysaccharide Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal B Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ABC Meningococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcus B Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Meningococcemia (Meningococcal Infections) - Recent Pipeline Updates
  • Meningococcemia (Meningococcal Infections) - Dormant Projects
  • Meningococcemia (Meningococcal Infections) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 24, 2014: Novartis provides second US university with Bexsero to help protect students and staff against potentially deadly meningitis B disease
      • Dec 09, 2013: Health Canada Approves Bexsero, the First Vaccine Available to Prevent Meningococcal Serogroup B
      • Jan 14, 2013: Novartis's Bexsero Shows Potential To Help Provide Broad Protection To Infants Against MenB In Phase III Clinical Trial
      • Dec 03, 2012: Sanofi Pasteur Canada Receives Health Canada Approval Of Menactra Meningococcal Conjugate Vaccine Indication For Infants
      • Nov 08, 2012: Sanofi Pasteur Announces Publication Of Pivotal Safety And Immunogenicity Data Of Menactra Vaccine For Infants And Toddlers
      • Feb 13, 2012: FDA Requests Additional Data On Novartis's Quadrivalent Meningococcal Conjugate Vaccine, Menveo For Expanded Use In Infants And Toddlers
      • Jun 16, 2011: FDA Accepts Novartis's Menveo sBLA For Review
      • May 12, 2011: Novartis Provides Update On Phase III Study Of Menveo Vaccine To Treat Meningococcal Disease
      • Apr 22, 2011: Sanofi Pasteur Announces FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication for Infants
      • Jan 31, 2011: FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo, for use in children from 2 years of age
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Meningococcemia (Meningococcal Infections), H1 2014
  • Number of Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by GlaxoSmithKline plc, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Biological E. Limited, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Novartis AG, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Panacea Biotec Limited, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Wellstat Vaccines, LLC, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Sanofi Pasteur SA, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Meningococcemia (Meningococcal Infections) Therapeutics - Recent Pipeline Updates, H1 2014
  • Meningococcemia (Meningococcal Infections) - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Meningococcemia (Meningococcal Infections), H1 2014
  • Number of Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top